Home › Research › Prevention and risk
Recombinant zoster vaccine is associated with a reduced risk of dementia
Emily A. Rayens, Lina S. Sy, Lei Qian, Bradley K. Ackerson, Julia E. Tubert, Yi Luo, Punam P. Modha, Raul Calderon et al.. Nature Communications, 2026-02-09
Topic: Risk, prevention and care in population studies
Plain-language summary
Vaccines to prevent herpes zoster have been associated with reduced dementia risk. We conducted a retrospective matched cohort study of Kaiser Permanente Southern California members aged ≥65 years who received two doses of RZV 4 weeks-6 months apart between 01 April 2018 and 31 December 2020, with no dementia diagnoses or dementia medications prior to or within 6 months of their second RZV dose. Cox regression with inverse probability of treatment weighting was used to estimate adjusted hazard ratios (aHRs). The study included 65,800 RZV-vaccinated individuals and 263,200 unvaccinated matches. Vaccination with two doses of RZV was associated with a 51% lower risk of dementia (aHR: 0.49 [95% confidence interval (CI): 0.46-0.51]); aHRs were comparable across age, and racial and ethnic groups, but the risk reduction was stronger in females compared to males. In an evaluation of potential healthy vaccinee bias, the aHR of dementia for RZV compared to Tdap was 0.73 (95% CI: 0.67-0.79). Vaccination with two doses of RZV is associated with a statistically significant reduction in the risk of dementia in adults aged ≥65 years. After accounting for healthy vaccinee bias, RZV vaccination remains associated with a statistically significant lower risk of dementia.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study of 65,800 participants. This retrospective cohort study found that two doses of recombinant zoster vaccine were associated with a 51% lower risk of dementia in adults aged 65 and older, and the association remained significant after accounting for healthy vaccinee bias. Reported effect size: aHR: 0.49.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Rayens, E. A., Sy, L. S., Qian, L., Ackerson, B. K., Tubert, J. E., Luo, Y., et al. (2026). Recombinant zoster vaccine is associated with a reduced risk of dementia. Nature Communications. https://doi.org/10.1038/s41467-026-69289-0
Vancouver
Rayens EA, Sy LS, Qian L, Ackerson BK, Tubert JE, Luo Y, et al. Recombinant zoster vaccine is associated with a reduced risk of dementia. Nature Communications. 2026. doi:10.1038/s41467-026-69289-0. PMID: 41663414.
BibTeX
@article{rayens2026-41663414,
author = {Rayens, Emily A. and Sy, Lina S. and Qian, Lei and Ackerson, Bradley K. and Tubert, Julia E. and Luo, Yi and Modha, Punam P. and Calderon, Raul and others},
title = {{Recombinant zoster vaccine is associated with a reduced risk of dementia}},
journal = {Nature Communications},
year = {2026},
doi = {10.1038/s41467-026-69289-0},
pmid = {41663414},
url = {https://doi.org/10.1038/s41467-026-69289-0}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Vaccines to prevent herpes zoster have been associated with reduced dementia risk.
- Vaccination with two doses of RZV was associated with a 51% lower risk of dementia (aHR: 0.49 [95% confidence interval (CI): 0.46-0.51]); aHRs were comparable across age, and racial and ethnic groups, but the risk reduction was stronger in females compared to males.
- In an evaluation of potential healthy vaccinee bias, the aHR of dementia for RZV compared to Tdap was 0.73 (95% CI: 0.67-0.79).
- Vaccination with two doses of RZV is associated with a statistically significant reduction in the risk of dementia in adults aged ≥65 years.
- After accounting for healthy vaccinee bias, RZV vaccination remains associated with a statistically significant lower risk of dementia.
Why it matters
This retrospective cohort study found that two doses of recombinant zoster vaccine were associated with a 51% lower risk of dementia in adults aged 65 and older, and the association remained significant after accounting for healthy vaccinee bias. The study is observational, so it cannot prove that the vaccine causes the reduced risk.
New to this subject? Start with our plain-English guide: Prevention →
Study details
- Study designcohort study
- Participants65,800
- Effect sizeaHR: 0.49
- Evidence strengthModerate
How this study scored 68/100
Published in a leading specialty journal, and it is a cohort study following people over time. Scored zero for randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Nature Communications) |
| Journal's citation record | 4 / 4 | Nature Communications: journal h-index 747 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 4 / 4 | 65,800 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 14 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 7.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 6 / 6 | Cited 62.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 14 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Hung Fu Tseng: h-index 45 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | University of Maryland, Baltimore: institution h-index 970 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41663414) |
| Free to read | 2 / 2 | Free to read |
| Total | 68 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1038/s41467-026-69289-0
- PubMed: 41663414
- Original source →
- Free full text: Nature Communications →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Prevention and risk from nearby years
Also tagged “biobank”
1,084 studies in the library carry the topic tag “biobank”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,084 tagged studies.